Biogen Inc (NASDAQ:BIIB) Shares Sold by Meiji Yasuda Asset Management Co Ltd.

AQR Capital Management LLC grew its holdings in shares of Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns …

Biogen logoMeiji Yasuda Asset Management Co Ltd. decreased its stake in Biogen Inc (NASDAQ:BIIB) by 6.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,866 shares of the biotechnology company’s stock after selling 452 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Biogen were worth $2,066,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Biogen by 0.4% in the fourth quarter. BlackRock Inc. now owns 16,568,963 shares of the biotechnology company’s stock worth $4,985,931,000 after acquiring an additional 70,603 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Biogen by 27,620.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock worth $48,000 after buying an additional 14,257,427 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Biogen by 6.5% during the third quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock worth $1,068,422,000 after buying an additional 183,542 shares in the last quarter. Capital World Investors grew its holdings in shares of Biogen by 503.2% during the third quarter. Capital World Investors now owns 2,473,708 shares of the biotechnology company’s stock worth $873,986,000 after buying an additional 2,063,598 shares in the last quarter. Finally, Jackson Square Partners LLC grew its holdings in shares of Biogen by 5.7% during the third quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock worth $792,042,000 after buying an additional 121,072 shares in the last quarter. 88.94% of the stock is currently owned by institutional investors and hedge funds.

BIIB has been the subject of a number of research reports. Oppenheimer set a $372.00 price objective on Biogen and gave the stock a “buy” rating in a report on Friday, January 25th. Morgan Stanley increased their price objective on Biogen from $394.00 to $401.00 and gave the stock an “overweight” rating in a report on Wednesday, December 19th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Biogen in a research report on Thursday, January 10th. Citigroup increased their price target on Biogen from $372.00 to $380.00 and gave the company an “outperform” rating in a research report on Wednesday, January 30th. Finally, ValuEngine raised Biogen from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Ten research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Biogen currently has an average rating of “Buy” and a consensus target price of $370.28.

Shares of BIIB traded down $7.36 during midday trading on Friday, hitting $307.93. The company’s stock had a trading volume of 1,601,073 shares, compared to its average volume of 1,225,704. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.04 and a current ratio of 2.32. Biogen Inc has a one year low of $249.17 and a one year high of $388.67. The firm has a market cap of $60.57 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 1.15 and a beta of 1.13.

Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.72 by $0.27. Biogen had a return on equity of 40.53% and a net margin of 32.94%. The business had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter in the prior year, the firm earned $5.26 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, research analysts forecast that Biogen Inc will post 28.68 EPS for the current fiscal year.

In related news, Director Alexander J. Denner bought 30,000 shares of the business’s stock in a transaction on Wednesday, January 30th. The shares were purchased at an average cost of $324.86 per share, with a total value of $9,745,800.00. Following the acquisition, the director now owns 10,909 shares of the company’s stock, valued at $3,543,897.74. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Alexander J. Denner bought 7,000 shares of the business’s stock in a transaction on Friday, February 1st. The shares were bought at an average cost of $328.45 per share, for a total transaction of $2,299,150.00. Following the completion of the acquisition, the director now directly owns 10,909 shares in the company, valued at approximately $3,583,061.05. The disclosure for this purchase can be found here. 0.29% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/10/meiji-yasuda-asset-management-co-ltd-has-2-07-million-position-in-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Further Reading: What is the float in trading stocks?

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Samlyn Capital Lowered Its Biogen (BIIB) Stake by $16.68 Million; Shares Declined; Qualcomm …

… of the Holding of the Annual Meeting; 11/04/2018 – Brain Corp CEO Dr. Eugene lzhikevich to Speak at CONNECT; 14/05/2018 – Gulf News: Trump, …

Biogen Inc. (NASDAQ:BIIB) Logo

Mathes Company Inc increased its stake in Qualcomm Inc. (QCOM) by 190% based on its latest 2018Q4 regulatory filing with the SEC. Mathes Company Inc bought 5,700 shares as the company’s stock declined 5.07% while stock markets rallied. The institutional investor held 8,700 shares of the radio and television broadcasting and communications equipment company at the end of 2018Q4, valued at $495,000, up from 3,000 at the end of the previous reported quarter. Mathes Company Inc who had been investing in Qualcomm Inc. for a number of months, seems to be bullish on the $64.76B market cap company. The stock decreased 0.96% or $0.52 during the last trading session, reaching $53.51. About 2.71 million shares traded. QUALCOMM Incorporated (NASDAQ:QCOM) has declined 17.21% since March 8, 2018 and is downtrending. It has underperformed by 21.58% the S&P500. Some Historical QCOM News: 19/03/2018 – FierceWireEurope: Qualcomm: It’s not over; 16/03/2018 – Qualcomm: Board Will Consist of 10 Directors Effective as of the Holding of the Annual Meeting; 11/04/2018 – Brain Corp CEO Dr. Eugene lzhikevich to Speak at CONNECT; 14/05/2018 – Gulf News: Trump, Xi ease trade tensions with ZTE, Qualcomm reversals; 05/03/2018 – QUALCOMM – BROADCOM HAS BEEN INTERACTING WITH CFIUS “FOR WEEKS” AND MADE TWO WRITTEN SUBMISSIONS TO CFIUS; 07/05/2018 – VentureBeat: Microsoft open-sources Azure IoT Edge runtime, embraces more Kubernetes, partners with DJI and Qualcomm #Build2018; 15/03/2018 – REFILE-UPDATE 3-With Qualcomm behind it, Broadcom looks to smaller deals; 08/03/2018 – blacq: Exclusive: Secretive U.S. security panel discussing Broadcom’s Qualcomm bid – sources WASHINGTON (Reuters); 09/03/2018 – Qualcomm: Focused on Maximizing Holder Value; Will Consider All Options to Achieve That Objective; 16/03/2018 – JACOBS SEES CLEAR MERITS TO EXPLORING PATH TO TAKE QCOM PRIVATE

Samlyn Capital Llc decreased its stake in Biogen Inc (BIIB) by 30.18% based on its latest 2018Q4 regulatory filing with the SEC. Samlyn Capital Llc sold 55,606 shares as the company’s stock declined 1.50% while stock markets rallied. The hedge fund held 128,645 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $38.71 million, down from 184,251 at the end of the previous reported quarter. Samlyn Capital Llc who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $60.89 billion market cap company. The stock decreased 1.82% or $5.75 during the last trading session, reaching $309.54. About 255,437 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 8, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 17/05/2018 – FDA’S GOTTLIEB – COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC; 12/03/2018 – Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia; 20/04/2018 – BIOGEN INC – IN COLLABORATION, IONIS WILL BE RESPONSIBLE FOR IDENTIFICATION OF ANTISENSE DRUG CANDIDATES BASED ON SELECTED TARGETS; 05/04/2018 – Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira; 05/03/2018 VP McKenzie Disposes 110 Of Biogen Inc; 07/03/2018 – EMA- EMA RECOMMENDATION FOLLOWING 12 REPORTS OF SERIOUS INFLAMMATORY BRAIN DISORDERS WORLDWIDE, INCLUDING ENCEPHALITIS AND MENINGOENCEPHALITIS; 15/05/2018 – Bridgewater Adds Biogen, Exits Costco, Buys More Newfield: 13F; 24/04/2018 – Biogen Idec 1Q Net $1.2B; 20/04/2018 – FDA: Biologic License Application (BLA): 125104 Company: BIOGEN IDEC; 05/04/2018 – BIOGEN INC – UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on April, 23. They expect $6.90 EPS, up 14.05% or $0.85 from last year’s $6.05 per share. BIIB’s profit will be $1.36B for 11.22 P/E if the $6.90 EPS becomes a reality. After $6.99 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -1.29% negative EPS growth.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.10, from 1.01 in 2018Q3. It dropped, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Gradient Investments Ltd Liability Com has invested 0% in Biogen Inc. (NASDAQ:BIIB). 219,754 are held by Hsbc Hldgs Public Limited Company. Gam Holdg Ag owns 13,477 shares. Athena Capital Limited Liability Corp holds 0.04% in Biogen Inc. (NASDAQ:BIIB) or 410 shares. Gateway Invest Advisers Limited Liability Com reported 128,214 shares stake. Next Financial Group Incorporated reported 389 shares stake. 1,534 are owned by Alta Mngmt Limited Liability Company. Rhenman Partners Asset Management Ab invested in 2.06% or 60,000 shares. Raymond James Advisors Inc holds 26,643 shares or 0.04% of its portfolio. Moreover, Old National Financial Bank In has 0.22% invested in Biogen Inc. (NASDAQ:BIIB). Roberts Glore & Il accumulated 2,589 shares. The Michigan-based Comerica Bankshares has invested 0.12% in Biogen Inc. (NASDAQ:BIIB). Systematic Limited Partnership holds 5,600 shares or 0.05% of its portfolio. Amer Assets Investment Management Lc reported 8,000 shares stake. West Oak Capital Ltd Limited Liability Company stated it has 4,802 shares or 0% of all its holdings.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Nasdaq.com which released: “NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy – Nasdaq” on March 04, 2019, also Nasdaq.com with their article: “Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More – Nasdaq” published on March 06, 2019, Seekingalpha.com published: “Biogen down 3% after hours on Mylan patent challenge – Seeking Alpha” on February 06, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations – Nasdaq” published on March 04, 2019 as well as Seekingalpha.com‘s news article titled: “Time To Add Downside Protection To Biogen? – Seeking Alpha” with publication date: February 06, 2019.

Samlyn Capital Llc, which manages about $7.24 billion and $4.21B US Long portfolio, upped its stake in Athene Hldg Ltd by 946,829 shares to 3.90 million shares, valued at $155.14 million in 2018Q4, according to the filing. It also increased its holding in Walmart Inc (NYSE:WMT) by 107,995 shares in the quarter, for a total of 214,622 shares, and has risen its stake in Kohls Corp (NYSE:KSS).

Since September 26, 2018, it had 1 buy, and 1 sale for $20.22 million activity. 1,000 shares were sold by Ehlers Michael D, worth $350,000.

Mathes Company Inc, which manages about $240.09M and $158.52 million US Long portfolio, decreased its stake in John Bean Technologies Corp. (NYSE:JBT) by 6,080 shares to 28,555 shares, valued at $2.05 million in 2018Q4, according to the filing. It also reduced its holding in Union Pacific Corp (NYSE:UNP) by 4,943 shares in the quarter, leaving it with 20,422 shares, and cut its stake in Salesforce.Com Inc (NYSE:CRM).

Since September 27, 2018, it had 0 insider buys, and 8 sales for $12.25 million activity. 40,000 shares valued at $2.03 million were sold by THOMPSON JAMES H on Monday, February 11. Rosenberg Donald J sold $347,746 worth of stock. 853 QUALCOMM Incorporated (NASDAQ:QCOM) shares with value of $54,166 were sold by ROGERS ALEXANDER H.

Investors sentiment decreased to 0.73 in 2018 Q4. Its down 0.04, from 0.77 in 2018Q3. It is negative, as 91 investors sold QCOM shares while 491 reduced holdings. 104 funds opened positions while 322 raised stakes. 1.00 billion shares or 4.55% less from 1.05 billion shares in 2018Q3 were reported. Private Advisor Ltd Co holds 0.06% or 46,141 shares in its portfolio. Employees Retirement System Of Texas holds 266,886 shares or 0.24% of its portfolio. Park Circle Com has invested 0.04% in QUALCOMM Incorporated (NASDAQ:QCOM). Klingenstein Fields & Limited Liability Company holds 6,157 shares or 0.01% of its portfolio. Causeway Cap Management Ltd Liability Corp reported 2.13% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). Proshare Advsr Llc has 0.39% invested in QUALCOMM Incorporated (NASDAQ:QCOM) for 986,769 shares. Td Management Ltd Liability owns 101 shares for 0% of their portfolio. The Ohio-based Cleararc Capital has invested 0.35% in QUALCOMM Incorporated (NASDAQ:QCOM). Loring Wolcott Coolidge Fiduciary Limited Liability Partnership Ma owns 210,264 shares for 0.22% of their portfolio. Walter And Keenan Fincl Consulting Communications Mi Adv invested 0.62% of its portfolio in QUALCOMM Incorporated (NASDAQ:QCOM). 212,021 were accumulated by Thompson Siegel And Walmsley Lc. Brown Advisory owns 178,927 shares or 0.03% of their US portfolio. Usca Ria Limited Liability Co reported 160,451 shares or 1.21% of all its holdings. The New York-based Kimelman Baird Ltd Liability Company has invested 0.09% in QUALCOMM Incorporated (NASDAQ:QCOM). Spirit Of America Mgmt Corp accumulated 7,200 shares.

QUALCOMM Incorporated (NASDAQ:QCOM) Institutional Positions Chart

Related Posts:

  • No Related Posts

Cullen Capital Management Boosted Position in Intel Corp. (INTC) as Valuation Rose; Bb&T Has …

… 08/05/2018 – Movellus Closes Funding From Intel Capital for Digital Tool Expansion Technology; 27/03/2018 – Xplore Wins Best PC Client Platform …

Biogen Inc. (NASDAQ:BIIB) Logo

Bb&T Corp increased its stake in Biogen Inc (BIIB) by 988.16% based on its latest 2018Q4 regulatory filing with the SEC. Bb&T Corp bought 19,615 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 21,600 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $6.50 million, up from 1,985 at the end of the previous reported quarter. Bb&T Corp who had been investing in Biogen Inc for a number of months, seems to be bullish on the $62.09 billion market cap company. The stock decreased 0.73% or $2.32 during the last trading session, reaching $315.65. About 587,894 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 7, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 13/04/2018 – Brightwire: Biogen likely to exercise option to raise stake in Samsung Bioepis, insiders say; 05/04/2018 – BIOGEN & SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE; 01/05/2018 – BIIB TO MAKE 1-TIME $50M PAYMENT TO NEURIMMUNE FOR 5% REDUCTION; 20/04/2018 – BIOGEN WILL PAY IONIS $1B IN CASH; 25/05/2018 – Biogen’s Avonex Sales Rise; Multiple Sclerosis Market Up 1%; 01/05/2018 – BIOGEN, NEURIMMUNE OPTION EXERCISE FOR ALZHEIMER’S TREATMENT; 24/04/2018 – BIOGEN 1Q REV. $3.1B, EST. $3.15B; 17/05/2018 – FDA’S GOTTLIEB – COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC; 24/04/2018 – Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism; 12/03/2018 – Biogen To Buy Schizophrenia Treatment From Pfizer For Up To $590 Million — MarketWatch

Cullen Capital Management Llc increased its stake in Intel Corp. (INTC) by 0.91% based on its latest 2018Q4 regulatory filing with the SEC. Cullen Capital Management Llc bought 7,575 shares as the company’s stock rose 10.40% with the market. The institutional investor held 838,550 shares of the semiconductors company at the end of 2018Q4, valued at $39.35 million, up from 830,975 at the end of the previous reported quarter. Cullen Capital Management Llc who had been investing in Intel Corp. for a number of months, seems to be bullish on the $236.07 billion market cap company. The stock decreased 0.86% or $0.46 during the last trading session, reaching $52.49. About 12.35M shares traded. Intel Corporation (NASDAQ:INTC) has risen 12.75% since March 7, 2018 and is uptrending. It has outperformed by 8.38% the S&P500. Some Historical INTC News: 02/04/2018 – APPLE IS PLANNING TO MOVE FROM INTEL CHIPS TO ITS OWN MAC CHIPS – CNBC, CITING REPORT; 20/04/2018 – House Intel Dems: Intel Ranking Member Schiff Statement on Comey Memos; 16/04/2018 – Tech Report: Rumor: Intel partner docs add to eight-core Coffee Lake CPU chatter; 12/03/2018 – Australian Gov: WIPO PUBLISHES PATENT OF INTEL FOR “MAINTAINING A SOURCE ENB CONNECTION DURING HANDOVER” (CHINESE, AMERICAN; 26/04/2018 – INTEL CORP – CO EXPECTS FULL YEAR TAX RATE OF 13 PERCENT, ONE POINT LOWER THAN PRIOR ESTIAMTE – CFO, CONF CALL; 22/05/2018 – Intel Finds Another Chip Exploit, Says Fix Is in Place (Correct); 04/04/2018 – GigaSpaces InsightEdge Platform with Intel® Technology Accelerates AI Innovations; 26/04/2018 – INTEL CORP – KELLER JOINS INTEL FROM TESLA; 08/05/2018 – Movellus Closes Funding From Intel Capital for Digital Tool Expansion Technology; 27/03/2018 – Xplore Wins Best PC Client Platform at Intel Technology Partner Awards

Since October 25, 2018, it had 2 buys, and 9 sales for $893,356 activity. $245,993 worth of stock was bought by SWAN ROBERT HOLMES on Thursday, December 6. $102,050 worth of stock was sold by Rodgers Steven Ralph on Thursday, October 25. McBride Kevin Thomas also sold $295,945 worth of Intel Corporation (NASDAQ:INTC) on Tuesday, October 30.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Seekingalpha.com which released: “Intel -1.4% on new security issue report – Seeking Alpha” on March 05, 2019, also Nasdaq.com with their article: “After Hours Most Active for Mar 1, 2019 : ABEV, GE, XOM, PFE, AR, TSM, SGMS, AAPL, SHY, MSFT, MCHI, INTC – Nasdaq” published on March 01, 2019, Marketwatch.com published: “If you own Apple, Amazon, Facebook or AMD, look out below – MarketWatch” on February 07, 2019. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “Intel (INTC) Ups the Ante in Hardware Security With SGX Card – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “3 Big Stock Charts for Thursday: Conagra Brands, Intel and Franklin Resources – Nasdaq” with publication date: February 14, 2019.

Investors sentiment increased to 1 in 2018 Q4. Its up 0.15, from 0.85 in 2018Q3. It is positive, as 52 investors sold INTC shares while 677 reduced holdings. 141 funds opened positions while 588 raised stakes. 2.96 billion shares or 3.57% more from 2.86 billion shares in 2018Q3 were reported. Warren Averett Asset Mngmt Limited Com, a Alabama-based fund reported 10,874 shares. Plancorp Limited Liability Company invested in 6,265 shares. Alpha Cubed Limited stated it has 415,943 shares or 2.92% of all its holdings. Lincoln Cap Ltd owns 5,845 shares. Cullen Frost Bankers Inc has 0.34% invested in Intel Corporation (NASDAQ:INTC) for 196,031 shares. Community Grp Inc Ltd reported 1.11% of its portfolio in Intel Corporation (NASDAQ:INTC). Private Wealth Advsr reported 57,626 shares stake. Of Vermont reported 1% in Intel Corporation (NASDAQ:INTC). Provise Grp Inc Ltd Llc reported 19,704 shares or 0.15% of all its holdings. Lingohr & Partner Asset Mgmt Gmbh holds 0.88% in Intel Corporation (NASDAQ:INTC) or 17,476 shares. Raymond James And Associate has 3.69M shares. West Oak Ltd Liability Corporation reported 47,471 shares. Comerica Bancorporation holds 0.74% in Intel Corporation (NASDAQ:INTC) or 1.87M shares. Cap Rech Global Investors owns 97.61 million shares. Aldebaran reported 8,304 shares.

Cullen Capital Management Llc, which manages about $3.87 billion and $2.32B US Long portfolio, decreased its stake in Vale Sa (Adr) (NYSE:VALE) by 288,350 shares to 791,450 shares, valued at $10.44 million in 2018Q4, according to the filing. It also reduced its holding in Allianz Se by 3,600 shares in the quarter, leaving it with 25,855 shares, and cut its stake in Royal Dutch Shell Class B (RYDBF).

Since September 26, 2018, it had 1 buy, and 1 insider sale for $20.22 million activity. DENNER ALEXANDER J also bought $20.57M worth of Biogen Inc. (NASDAQ:BIIB) on Wednesday, January 30.

Investors sentiment decreased to 0.91 in 2018 Q4. Its down 0.10, from 1.01 in 2018Q3. It turned negative, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Moreover, Aperio Group Ltd has 0.24% invested in Biogen Inc. (NASDAQ:BIIB) for 160,705 shares. Ferguson Wellman Cap Management invested 0.04% in Biogen Inc. (NASDAQ:BIIB). Rathbone Brothers Public Ltd Co reported 0.04% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Everence Cap Mngmt reported 0.33% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Wolverine Asset Limited Liability Corp reported 0% in Biogen Inc. (NASDAQ:BIIB). Louisiana State Employees Retirement System accumulated 10,600 shares or 0.18% of the stock. State Street holds 0.24% in Biogen Inc. (NASDAQ:BIIB) or 8.78 million shares. 3,074 are held by Walleye Trading Limited Liability Co. 4,231 are owned by Bremer Tru Natl Association. Highvista Strategies Ltd Company invested in 7.47% or 28,709 shares. Midas Mngmt Corporation reported 1,400 shares. Prudential Public Limited Co invested 0.14% in Biogen Inc. (NASDAQ:BIIB). Amica Pension Fund Board Of Trustees owns 6,442 shares or 0.3% of their US portfolio. Community Serv Group has 0.08% invested in Biogen Inc. (NASDAQ:BIIB). Mairs And Incorporated invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Bb&T Corp, which manages about $4.88B US Long portfolio, decreased its stake in Ford Motor Compa (NYSE:F) by 52,045 shares to 86,354 shares, valued at $661,000 in 2018Q4, according to the filing. It also reduced its holding in Dowdupont Inc by 13,641 shares in the quarter, leaving it with 127,935 shares, and cut its stake in Lam Research Cor (NASDAQ:LRCX).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Seekingalpha.com which released: “Biogen’s Spinraza OK’d in China – Seeking Alpha” on February 28, 2019, also Seekingalpha.com with their article: “Biogen 2019 Outlook – Seeking Alpha” published on February 11, 2019, Nasdaq.com published: “Surprising Analyst 12-Month Target For OEW – Nasdaq” on February 25, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Fool.com and their article: “Here’s Why Ionis Pharmaceuticals Jumped Higher Today – Motley Fool” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Notable ETF Outflow Detected – IBB, BIIB, ILMN, REGN – Nasdaq” with publication date: February 14, 2019.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Clearbridge Has Cut Cisco Sys (CSCO) Position by $1.62 Million; Biogen (BIIB) Position Boosted …

Some Historical CSCO News: 06/03/2018 – IDG VENTURES INDIA SAYS CISCO INVESTMENTS INVESTS IN IDG’S THIRD FUND; 01/05/2018 …

Biogen Inc. (NASDAQ:BIIB) Logo

Clearbridge Llc decreased its stake in Cisco Sys Inc (CSCO) by 20.47% based on its latest 2018Q4 regulatory filing with the SEC. Clearbridge Llc sold 37,575 shares as the company’s stock rose 8.18% with the market. The institutional investor held 146,014 shares of the technology company at the end of 2018Q4, valued at $6.33 million, down from 183,589 at the end of the previous reported quarter. Clearbridge Llc who had been investing in Cisco Sys Inc for a number of months, seems to be less bullish one the $225.82B market cap company. The stock increased 0.27% or $0.14 during the last trading session, reaching $51.3. About 14.99M shares traded. Cisco Systems, Inc. (NASDAQ:CSCO) has risen 16.80% since March 6, 2018 and is uptrending. It has outperformed by 12.43% the S&P500. Some Historical CSCO News: 06/03/2018 – IDG VENTURES INDIA SAYS CISCO INVESTMENTS INVESTS IN IDG’S THIRD FUND; 01/05/2018 – CISCO: ROWAN TROLLOPE TO BECOME CEO AT ANOTHER FIRM AS OF MAY 3; 01/05/2018 – Transaction Expected to Close in Cisco’s 1Q19; 15/05/2018 – Leading Marketing Innovators from Marketo and Cisco to Keynote This Year’s BRAND INNOVATION QUEST® in Chicago; 23/05/2018 – Ukraine cyber police aware of possible new threat -police chief; 26/03/2018 – Silicon Valley Business Journal: Breaking: Cisco pledges $50 million over five years to wipe out #homelessness in Santa Clara; 10/05/2018 – Former Cisco CEO John Chambers Joins Bloom Energy Bd of Directors; 16/05/2018 – Cisco Systems 3Q GAAP Total Gross Margin and Pdt Gross Margin Were 62.3% and 61.0%, Respectively; 23/05/2018 – Cyber firms warn on suspected Russian plan to attack Ukraine; 30/05/2018 – Cisco Announces June 2018 Events with the Financial Community

Sabby Management Llc increased its stake in Biogen Inc (BIIB) by 254.52% based on its latest 2018Q4 regulatory filing with the SEC. Sabby Management Llc bought 90,441 shares as the company’s stock declined 1.50% while stock markets rallied. The hedge fund held 125,975 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $37.91M, up from 35,534 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Biogen Inc for a number of months, seems to be bullish on the $64.30B market cap company. The stock decreased 0.12% or $0.39 during the last trading session, reaching $326.87. About 1.02M shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since March 6, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 24/04/2018 – BIOGEN 1Q REV. $3.1B, EST. $3.15B; 20/04/2018 – BIOGEN WILL PAY IONIS $1B IN CASH; 20/04/2018 – BIOGEN INC – WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF COLLABORATION AND WILL BE RESPONSIBLE FOR THEIR DEVELOPMENT AND COMMERCIALIZATION; 12/03/2018 – BIOGEN: SPINRAZA TRIAL SHOWED IMPROVED MOTOR FUNCTION; 14/05/2018 – Primecap Adds Moody’s, Exits Constellium, Cuts Biogen: 13F; 13/04/2018 – Biogen likely to exercise option to raise stake in Samsung Bioepis, insiders say; 31/05/2018 – Biogen Appoints Daniel Karp as EVP, Corporate Development; 05/04/2018 – Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in; 24/04/2018 – Biogen Idec 1Q Rev $3.1B; 01/05/2018 – BIIB TO MAKE 1-TIME $50M PAYMENT TO NEURIMMUNE FOR 5% REDUCTION

Investors sentiment increased to 0.91 in 2018 Q4. Its up 0.06, from 0.85 in 2018Q3. It increased, as 68 investors sold CSCO shares while 701 reduced holdings. 140 funds opened positions while 557 raised stakes. 3.17 billion shares or 0.63% more from 3.15 billion shares in 2018Q3 were reported. Penbrook Mngmt Ltd Liability, New York-based fund reported 26,700 shares. Waters Parkerson & Co Ltd Liability Co owns 9,391 shares for 0.04% of their portfolio. Thomasville Fincl Bank owns 17,726 shares. Amer Research Mngmt reported 0.03% in Cisco Systems, Inc. (NASDAQ:CSCO). Lesa Sroufe And stated it has 5,811 shares or 0.21% of all its holdings. Burney Com owns 143,765 shares. Etrade Capital Mngmt Limited Liability Com holds 0.38% or 268,634 shares in its portfolio. Walleye Trading Limited Co reported 13,816 shares. 1.06M were accumulated by Country Trust Bank & Trust. Moreover, Fort Point Capital Partners Ltd Com has 0.21% invested in Cisco Systems, Inc. (NASDAQ:CSCO). 32,107 were reported by B Riley Wealth Mngmt Inc. 6,608 were reported by Jones Financial Cos Lllp. Voya Invest Management Ltd Liability Company holds 0.63% or 5.89M shares. Cypress Asset Inc Tx invested in 11,745 shares. Wealth Architects Ltd Liability Company invested in 0.1% or 6,276 shares.

Analysts await Cisco Systems, Inc. (NASDAQ:CSCO) to report earnings on May, 15. They expect $0.68 EPS, up 13.33% or $0.08 from last year’s $0.6 per share. CSCO’s profit will be $2.99B for 18.86 P/E if the $0.68 EPS becomes a reality. After $0.67 actual EPS reported by Cisco Systems, Inc. for the previous quarter, Wall Street now forecasts 1.49% EPS growth.

More notable recent Cisco Systems, Inc. (NASDAQ:CSCO) news were published by: Seekingalpha.com which released: “Cisco raises dividend by 6% – Seeking Alpha” on February 13, 2019, also Nasdaq.com with their article: “Pre-Market Most Active for Feb 14, 2019 : SQQQ, QQQ, ERIC, CSCO, CYBR, AMD – Nasdaq” published on February 14, 2019, Investorplace.com published: “Tuesday’s Vital Data: General Electric, Alibaba and Cisco – Investorplace.com” on February 26, 2019. More interesting news about Cisco Systems, Inc. (NASDAQ:CSCO) were released by: Nasdaq.com and their article: “Technology Sector Update for 02/15/2019: MRIN, LOGM, TLND, MSFT, AAPL, CSCO, IBM, GOOG – Nasdaq” published on February 15, 2019 as well as Nasdaq.com‘s news article titled: “3 “Internet of Things” Stocks to Buy Right Now – Nasdaq” with publication date: February 22, 2019.

Since September 11, 2018, it had 0 insider purchases, and 10 sales for $27.62 million activity. $3.32M worth of Cisco Systems, Inc. (NASDAQ:CSCO) was sold by Kramer Kelly A.. $196,324 worth of stock was sold by CHANDLER MARK D on Friday, November 23. Tan Irving sold $1.36 million worth of stock. $3.00 million worth of stock was sold by Goeckeler David on Tuesday, September 18. $1.20M worth of stock was sold by WEST STEVEN M on Wednesday, December 12. 217,420 shares were sold by Robbins Charles, worth $10.28M on Monday, September 17.

Investors sentiment decreased to 0.91 in 2018 Q4. Its down 0.10, from 1.01 in 2018Q3. It worsened, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Gradient Investments Limited Liability has invested 0% in Biogen Inc. (NASDAQ:BIIB). Meiji Yasuda Life Ins has invested 0.28% in Biogen Inc. (NASDAQ:BIIB). Cibc World Markets invested 0.02% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Financial Architects Incorporated invested in 0.01% or 108 shares. Commerzbank Aktiengesellschaft Fi accumulated 135,222 shares or 0.44% of the stock. Stifel Fin Corporation invested in 242,942 shares or 0.24% of the stock. Bridgewater Ltd Partnership reported 0.13% stake. 3,700 were accumulated by Continental Advsrs Ltd Liability. Mitchell Mgmt holds 1.8% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 14,183 shares. First Interstate Commercial Bank accumulated 836 shares. Brown Brothers Harriman And invested 0.01% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Utd Capital Financial Advisers Limited Liability Corp holds 63,482 shares. 915 are held by Reilly Finance Advisors Ltd Llc. Department Mb Savings Bank N A accumulated 29,521 shares. Moreover, Ancora Ltd Liability Co has 0.08% invested in Biogen Inc. (NASDAQ:BIIB) for 5,496 shares.

Since September 26, 2018, it had 1 insider purchase, and 1 insider sale for $20.22 million activity. The insider DENNER ALEXANDER J bought $20.57 million.

Cisco Systems, Inc. (NASDAQ:CSCO) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Ionis Pharmaceuticals (IONS) PT Set at $71.00 by Morgan Stanley

Two Sigma Investments LP now owns 727,545 shares of the company’s stock worth $39,331,000 after acquiring an additional 187,876 shares during …

Ionis Pharmaceuticals logoIonis Pharmaceuticals (NASDAQ:IONS) received a $71.00 target price from equities researchers at Morgan Stanley in a note issued to investors on Friday. The brokerage presently has a “hold” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 1.88% from the company’s current price.

Several other analysts have also weighed in on the stock. Piper Jaffray Companies set a $63.00 price objective on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday. BMO Capital Markets raised their price target on shares of Ionis Pharmaceuticals from $70.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday. ValuEngine raised shares of Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Wednesday, January 2nd. Finally, TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, December 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $60.57.

Shares of NASDAQ IONS traded down $1.30 during mid-day trading on Friday, hitting $69.69. 1,708,728 shares of the stock were exchanged, compared to its average volume of 639,259. The firm has a market cap of $8.08 billion, a price-to-earnings ratio of 23.54 and a beta of 2.28. The company has a current ratio of 7.99, a quick ratio of 7.96 and a debt-to-equity ratio of 0.74. Ionis Pharmaceuticals has a twelve month low of $39.07 and a twelve month high of $72.20.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 27th. The company reported $2.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $2.20. The company had revenue of $192.00 million during the quarter, compared to analyst estimates of $159.59 million. Ionis Pharmaceuticals had a negative net margin of 7.52% and a negative return on equity of 1.58%. The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) earnings per share. On average, analysts forecast that Ionis Pharmaceuticals will post -0.18 earnings per share for the current year.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 77,000 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $60.77, for a total transaction of $4,679,290.00. Following the completion of the sale, the chairman now owns 109,634 shares of the company’s stock, valued at approximately $6,662,458.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director B Lynne Parshall sold 8,333 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $70.00, for a total transaction of $583,310.00. Following the sale, the director now directly owns 61,010 shares of the company’s stock, valued at approximately $4,270,700. The disclosure for this sale can be found here. In the last three months, insiders sold 197,326 shares of company stock valued at $12,114,304. 2.44% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IONS. FMR LLC grew its holdings in Ionis Pharmaceuticals by 8.7% during the 3rd quarter. FMR LLC now owns 20,463,839 shares of the company’s stock worth $1,055,525,000 after acquiring an additional 1,635,782 shares during the period. BlackRock Inc. grew its holdings in Ionis Pharmaceuticals by 5.8% during the 3rd quarter. BlackRock Inc. now owns 7,463,257 shares of the company’s stock worth $384,955,000 after acquiring an additional 408,678 shares during the period. Two Sigma Advisers LP grew its holdings in Ionis Pharmaceuticals by 96.9% during the 4th quarter. Two Sigma Advisers LP now owns 606,911 shares of the company’s stock worth $32,810,000 after acquiring an additional 298,700 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Ionis Pharmaceuticals by 252.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 410,699 shares of the company’s stock worth $22,202,000 after acquiring an additional 294,184 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Ionis Pharmaceuticals by 34.8% during the 4th quarter. Two Sigma Investments LP now owns 727,545 shares of the company’s stock worth $39,331,000 after acquiring an additional 187,876 shares during the period. 84.55% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

See Also: What factors cause inflation to rise?

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts